Jci_page_head_homepage_01 Jci_page_head_homepage_02
Nicholas Wallingford, Bertrand Perroud, Qian Gao, Anna Coppola, Erika Gyengesi, Zhong-Wu Liu, Xiao-Bing Gao, Adam Diament, Kari A. Haus, Zia Shariat-Madar, Fakhri Mahdi, Sharon L. Wardlaw, Alvin H. Schmaier, Craig H. Warden, Sabrina Diano
Published in Volume 119, Issue 8
J Clin Invest. 2009; 119(8):2291–2303 doi:10.1172/JCI37209
Abstract | Full text | PDF | Supplemental material
Options: View larger image (or click on image)
Jci37209
Figure 7
Schematic illustration showing that hypothalamic PRCP is in an anatomical position to determine the efficacy of released α-MSH1–13, thereby controlling the output of the melanocortin system.

We found that PRCP is mainly expressed in the lateral hypothalamic Hcrt and MCH neurons. These neurons project to various areas of the hypothalamus, such as the PVN, where α-MSH1–13 terminals strongly innervate MC4R-expressing neurons. It is our hypothesis that PRCP, once released from the Hcrt and/or MCH terminals, will degrade α-MSH, thus increasing the antagonist effect of agouti-related protein (AgRP) and enhancing the orexigenic tone of the system. In support of this, congenic mice and PRCPgt/gt mice are leaner than the wild-type controls. GHS-R/LR, growth hormone secretagogue receptor/leptin receptor; NPY, neuropeptide Y.